A new variety of hemp has been added to the catalog of the European Union. Its particularity: it has been selected for its high content of cannabigerol (CBG).
This new variety, named Enectarol, was developed for 5 years by the Italian-Dutch company Enecta. The strain produces 5.5% CBG and less than 0.1% THC.
“There is a lack of true hemp flower strains for cannabinoids in Europe, as most varieties in the catalog are spin-offs of fiber strains,” Paolini told HempToday. “New genetics for the industry are evolving at an incredible rate, but the common EU catalog does not reflect this evolution. The lack of new varieties is a sore point for the European hemp industry. »
What is CBG?
CBG (cannabigerol), is one of the 120 cannabinoids found in cannabis. CBG is known as the “mother” cannabinoid, the precursor to CBD, CBN, CBC and THC.
CBG activates both CB1 and CB2 receptors in the endocannabinoid system, offering the promise that it may hold the joint qualities of all other cannabinoids combined.
Studies have shown that CBG shows promise for conditions such as glaucoma, inflammatory bowel disease, and Huntington’s disease, and can inhibit tumor growth in some cases; it is known to kill or slow down bacteria and promote bone development.
Last year, the European Commission added CBG to the EU Cosmetic Ingredients Database (Cosing), indicating that the compound is safe to use in health and beauty products. When applied topically, CBG acts on the CB1 and CB2 endocannabinoid receptors, which are located in the skin.
According to its proponents, this hemp-derived compound has anti-inflammatory, antibacterial, and antioxidant properties that help the endocannabinoid system maintain healthy skin function.
